A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Weill Cornell Medical Centers, New York

Ospedale Papa Giovanni Xxiii, Bergamo

Emory University - Winship Cancer Institute, Atlanta

Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse

Johannes Wesling Klinikum Minden, Minden

Hospital Clinico Universitario de Valencia, Valencia

Franciscan St. Francis Health, Indianapolis

Azienda Ospedaliero-Universitaria Careggi (Aouc), Florence

Washington University School of Medicine, St Louis

University Hospital Mannheim, Mannheim

Centre Leon Berard, Lyon

Hospital Saint Louis, Paris

Md Anderson Cancer Center, Houston

University of Utah, Salt Lake City

Mayo Clinic Arizona, Phoenix

City of Hope National Medical Center, Duarte

Stanford Cancer Institute, Stanford

Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz, Linz

Medical University of Vienna, Vienna

Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus, Vienna

Universitair Ziekenhuis (Uz) Leuven, Leuven

Princess Margaret Cancer Center, Toronto

Chu de Nice - Hospital L Archet, Nice

University Medical Center Rwth Aachen, Aachen

Universitatsklinikum Halle (Saale), Halle

Universitatsklinikum Jena, Jena

Universitatsklinikum Leipzig, Leipzig

Kindai University Hospital, Osaka

Ntt Medical Center Tokyo, Tokyo

Inselspital - Universitaetsspital Bern, Bern

Universitatsspital Zurich, Zurich

Guys and St Thomas Nhs Foundation Trust, London

Oxford University Hospitals Nhs Foundation Trust, Oxford